Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

789.12 +6.77 (+0.87%)
Official Closing Price Updated: 7:00 PM EST, Dec 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,059,405
Open 777.13
Bid (Size) 788.00 (1)
Ask (Size) 790.00 (1)
Prev. Close 782.35
Today's Range 772.99 - 794.25
52wk Range 561.65 - 972.53
Shares Outstanding N/A
Dividend Yield 0.66%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eli Lilly Stock Soars 34.42% YTD: A $1000 Investment Outpaces Returns From These ETFs Holding Mounjaro-Maker Shares
Recently, the company announced a massive $15 billion share buyback plan and a 15% dividend increase. 
Via Benzinga
Topics ETFs
If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today
Via Benzinga

Performance

YTD
+33.25%
+33.25%
1 Month
-2.79%
-2.79%
3 Month
-14.57%
-14.57%
6 Month
-10.17%
-10.17%
1 Year
+37.56%
+37.56%

More News

Read More
Novo Nordisk's Ozempic Label Expansion Snags Approval From European Drug Regulator's Advisory Panel
Via Benzinga
Telehealth Firm Ro Partners With Eli Lilly to Boost Access to Obesity Drug Zepbound
Via Benzinga
Eli Lilly Stock Could Have a Huge Growth Catalyst in Early 2025
Via The Motley Fool
Eli Lilly Unusual Options Activity
Via Benzinga
2 No-Brainer Growth Stocks to Buy and Hold Through 2025 and Beyond
Via The Motley Fool
Eli Lilly's Investigational Cancer Drug Cuts Risk Of Death By 38% In Breast Cancer Patients
Via Benzinga
4 Stocks That Crushed Analyst Estimates by More Than Double
Via MarketBeat
Eli Lilly's $15 Billion Buyback Faces Stiff Resistance On The Charts
Via Benzinga
What's Going On With Eli Lilly Stock On Tuesday?
Via Benzinga
As Eli Lilly Shares Gain Over 35% YTD, Drugmaker Announces $15B Share Buyback Program And Boosts Dividend By 15%
Via Benzinga
Warning: This Skyrocketing Stock Has a Hidden Risk
Via The Motley Fool
Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown
Via Benzinga
Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Eli Lilly Stock Just Got Even Sweeter. Here's Why It's Worth Buying Now
Via The Motley Fool
MarketBeat Week in Review – 12/2 - 12/6
Via MarketBeat
Topics Economy Government Immigration
Exposures Economy Immigration Interest Rates
3 No-Brainer Growth Stocks to Buy in December
Via The Motley Fool
Could Eli Lilly Beat Rivals in the Billion-Dollar Weight Loss Drug Market in 2025? Evidence Is Piling Up, and Here's What It Says.
Via The Motley Fool
Eli Lilly Stock Price Analysis – Earnings Miss And The Pullback Worth Watching
Via Talk Markets
Topics Earnings Economy Stocks / Equities
Exposures Financial Supply Chain
Eli Lilly Investments In Production Reach $23 Billion With Additional $3 Billion Expansion At US Facility
Via Benzinga
Alzheimer’s Disease Therapy Provides Patients With Hope
Via Brandpoint
Stock Market Hits Highs On Salesforce, Tech Earnings; Bitcoin Tops $100,000, Briefly: Weekly Review
Via Investor's Business Daily
Amgen Stock Falls on Weight Loss Drug Data: Overreaction or Fair?
Via MarketBeat
Billionaire Izzy Englander Is Buying This Obesity Drug Stock That Could Soar Nearly 20%, According to Wall Street
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.